NASDAQ · RMD
Healthcare · Medical - Instruments & Supplies
$224.99
Down-$3.43 (-1.50%)
Updated Sep 20, 2026, 2:17 PM
SID Score
6.0/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
RMD closed at $224.99 after 19 trading sessions, down 3.21% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $228.21 | $228.385 | $224.56 | $224.99 | 3.86M |
| Sep 17, 2026 | $228.25 | $229.57 | $225.08 | $228.42 | 1.09M |
| Sep 16, 2026 | $228.19 | $229.325 | $224.26 | $228.25 | 1.07M |
| Sep 15, 2026 | $226.36 | $234.33 | $225.115 | $229.44 | 1.64M |
| Sep 14, 2026 | $221.04 | $225.82 | $220.94 | $222.99 | 989.01K |
| Sep 11, 2026 | $220.44 | $221.29 | $215.97 | $218.27 | 912.33K |
| Sep 10, 2026 | $217.93 | $221.253 | $215.80 | $219.58 | 923.14K |
| Sep 9, 2026 | $220.845 | $220.845 | $217.00 | $219.95 | 1.2M |
| Sep 8, 2026 | $226.22 | $226.665 | $220.445 | $221.05 | 1.96M |
| Sep 4, 2026 | $225.91 | $228.49 | $225.12 | $228.35 | 843.84K |
| Sep 3, 2026 | $231.20 | $233.045 | $227.265 | $229.19 | 1.48M |
| Sep 2, 2026 | $234.73 | $237.21 | $230.78 | $230.87 | 1.16M |
| Sep 1, 2026 | $239.90 | $242.40 | $230.175 | $231.36 | 987.08K |
| Aug 31, 2026 | $237.97 | $241.71 | $236.16 | $240.10 | 1.72M |
| Aug 28, 2026 | $236.64 | $241.06 | $235.01 | $240.33 | 1.39M |
| Aug 27, 2026 | $233.06 | $237.94 | $232.29 | $235.76 | 1.59M |
| Aug 26, 2026 | $233.66 | $237.76 | $232.10 | $235.69 | 1.54M |
| Aug 25, 2026 | $232.22 | $238.37 | $231.885 | $236.59 | 1.76M |
| Aug 24, 2026 | $231.00 | $233.23 | $228.87 | $232.45 | 1.11M |
The latest Smart Investors Daily articles mentioning RMD.
RMD research
Company profile and research snapshot.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | RBC Capital | Outperform | — |
| Aug 31, 2026 | Keybanc | Overweight | — |
| Aug 19, 2026 | Rothschild & Co | Neutral | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 7, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 19, 2026
ResMed Inc. (NYSE:RMD) is well positioned to benefit from the long-term growth of the global obstructive sleep apnea (OSA) treatment market. Likewise, the company remains well positioned to benefit from growing awareness and penetration in the global market, backed by a robust product portfolio. The company’s OSA portfolio includes CPAP and APAP machines, led by […]
Yahoo · Sep 15, 2026
Sleep device maker ResMed rose Tuesday after the stock notched an upgrade and price target increase on Wall Street. RBC Capital analysts boosted the stock’s rating to Outperform from Sector Perform on Tuesday, while lifting the price target to $262 from $244, citing growing demand for sleep apnea devices. The firm said that ResMed a top provider of devices for respiratory care and obstructive sleep apnea (OSA), is poised to gain market share as global awareness of the condition grows.
Yahoo · Sep 15, 2026
ResMed stock rallies on a bullish RBC Capital research note. Here’s why analyst Craig Wong-Pan raised his price target on RMD shares today.
Fintel · Sep 15, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RMD.
